Imaging contrast agent developer Target Laboratories said that its OTL38 intraoperative cancer imaging agent was found to be safe and efficacious for detecting ovarian cancer tumors in a phase II multicenter study.
In the study, a research team led by Dr. Leslie Randall of the University of California, Irvine reported that OTL38's near-infrared imaging helped surgeons to detect additional lesions in 48.3% of the patients compared with traditional detection techniques. It also yielded 97% sensitivity when controlling for detection correlation of multiple lesions within a single patient, according to the firm.
The research was published in the October issue of Gynecologic Oncology.
